- Report
- February 2025
- 200 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- May 2024
- 140 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- March 2021
- 102 Pages
Global
From €4314EUR$4,500USD£3,605GBP
- Report
- March 2024
- 174 Pages
Global
From €7190EUR$7,500USD£6,008GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1917EUR$2,000USD£1,602GBP
- Report
- January 2019
- 18 Pages
Global
From €9587EUR$10,000USD£8,010GBP
- Report
- April 2025
- 50 Pages
Global
From €2540EUR$2,650USD£2,123GBP
Fludarabine is a chemotherapy drug used to treat chronic lymphocytic leukemia (CLL). It is a purine analog, which works by interfering with the growth of cancer cells. It is usually given in combination with other drugs, such as cyclophosphamide and rituximab. Fludarabine is also used to treat other types of leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is also used to treat some types of non-Hodgkin's lymphoma.
Fludarabine is generally well-tolerated, but can cause side effects such as nausea, vomiting, diarrhea, and hair loss. It can also cause low white blood cell counts, which can increase the risk of infection.
Fludarabine is available in both generic and brand-name formulations. Some of the companies that produce fludarabine include Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more